ChikungunyaPipeline Review, H2 2015
Summary
Global Markets Directs, ChikungunyaPipeline Review, H2 2015, provides an overview of the Chikungunyas therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Chikungunya
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Chikungunya
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chikungunya Overview 9
Therapeutics Development 10
Pipeline Products for Chikungunya - Overview 10
Pipeline Products for Chikungunya - Comparative Analysis 11
Chikungunya - Therapeutics under Development by Companies 12
Chikungunya - Therapeutics under Investigation by Universities/Institutes 15
Chikungunya - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Chikungunya - Products under Development by Companies 19
Chikungunya - Products under Investigation by Universities/Institutes 21
Chikungunya - Companies Involved in Therapeutics Development 22
Abivax S.A. 22
Arbovax, Inc. 23
Arno Therapeutics, Inc. 24
Bharat Biotech International Limited 25
Etubics Corporation 26
Indian Immunologicals Limited 27
Inovio Pharmaceuticals, Inc. 28
Integral Molecular, Inc. 29
Merck & Co., Inc. 30
Nanotherapeutics, Inc. 31
PaxVax 32
Profectus BioSciences, Inc. 33
Takeda Pharmaceutical Company Limited 34
Themis Bioscience GmbH 35
Chikungunya - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ABX-309 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Antibody for Chikungunya - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AR-12 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chikungunya vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chikungunya vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chikungunya vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
chikungunya vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
chikungunya vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chikungunya vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
chikungunya vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
chikungunya vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
chikungunya vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
chikungunya vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
chikungunya vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chikungunya vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
chikungunya vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
chikungunya vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
chikungunya vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
chikungunya vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DEF-201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IMCKV-063 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibodies for Chikungunya - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MV-CHIK - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chikungunya - Recent Pipeline Updates 75
Chikungunya - Dormant Projects 78
Chikungunya - Product Development Milestones 79
Featured News & Press Releases 79
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 79
Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 80
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 81
Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1 82
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 83
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 83
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 84
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 84
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List Of Tables
Number of Products under Development for Chikungunya, H2 2015 10
Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Development by Companies, H2 2015 (Contd...1) 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd...1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Chikungunya - Pipeline by Abivax S.A., H2 2015 22
Chikungunya - Pipeline by Arbovax, Inc., H2 2015 23
Chikungunya - Pipeline by Arno Therapeutics, Inc., H2 2015 24
Chikungunya - Pipeline by Bharat Biotech International Limited, H2 2015 25
Chikungunya - Pipeline by Etubics Corporation, H2 2015 26
Chikungunya - Pipeline by Indian Immunologicals Limited, H2 2015 27
Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 28
Chikungunya - Pipeline by Integral Molecular, Inc., H2 2015 29
Chikungunya - Pipeline by Merck & Co., Inc., H2 2015 30
Chikungunya - Pipeline by Nanotherapeutics, Inc., H2 2015 31
Chikungunya - Pipeline by PaxVax, H2 2015 32
Chikungunya - Pipeline by Profectus BioSciences, Inc., H2 2015 33
Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 34
Chikungunya - Pipeline by Themis Bioscience GmbH, H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Stage and Target, H2 2015 38
Number of Products by Stage and Mechanism of Action, H2 2015 40
Number of Products by Stage and Route of Administration, H2 2015 42
Number of Products by Stage and Molecule Type, H2 2015 44
Chikungunya Therapeutics - Recent Pipeline Updates, H2 2015 75
Chikungunya - Dormant Projects, H2 2015 78
List Of Figures
Number of Products under Development for Chikungunya, H2 2015 10
Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Top 10 Targets, H2 2015 37
Number of Products by Stage and Top 10 Targets, H2 2015 37
Number of Products by Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Routes of Administration, H2 2015 41
Number of Products by Stage and Routes of Administration, H2 2015 41
Number of Products by Top 10 Molecule Types, H2 2015 43
Number of Products by Stage and Top 10 Molecule Types, H2 2015 43
